01/10/2026
🔴 What could change our diabetes practice?
1. 🫘 In CKD, eGFR alone tells only half the story.
Among transplant recipients with diabetes, CKD prevalence rose from 49.5% using reduced eGFR alone to 72.6% when albuminuria was also considered.
💡 Clinical message: Always think eGFR + UACR, not eGFR alone.
2. ⚠️ Normal glucose does NOT exclude dangerous ketosis.
PARTNER cases showed that people with T1D—particularly with SGLT2 inhibitor exposure—may develop clinically silent ketonaemia, especially with reduced insulin delivery, low-carbohydrate intake, illness or pump interruption.
💡 CME Pearl: When the clinical situation suggests ketosis, check ketones—not merely glucose. Continuous ketone monitoring is an emerging safety tool, not yet something required for every patient.
3. 🎯 “Low predicted risk” does not mean “low-risk diabetes.”
In the UK cohort, 11.8% of newly diagnosed T2D occurred despite low predicted risk. These patients were younger and leaner, yet had higher HbA1c, more subsequent insulin initiation and higher severe retinopathy and mortality.
💡 Clinical message: Don't let a reassuring risk score overrule clinical suspicion.
4. 📈 Metabolic trajectory may matter as much as a snapshot.
Longitudinal changes in insulin resistance/sensitivity indices added information for predicting future T2D. Interestingly, TyG and TG/HDL-C contributed particularly through their trajectories over time, rather than a single baseline measurement.
💡 Follow the metabolic movie—not just the photograph.
5. 💊 Don't always wait for monotherapy to fail.
Evidence presented from UKPDS follow-up, combination-treatment trials and VERIFY supports earlier proactive combination therapy for better glycaemic durability rather than therapeutic inertia.
💡 CME Pearl: “Treat-to-failure” is increasingly giving way to “treat-to-preserve.”
6. 👴 But early combination is NOT for everybody.
Frailty, dementia, multimorbidity, CKD/liver disease, polypharmacy, hypoglycaemia risk, adherence and treatment burden may make stepwise intensification—or even de-intensification—more appropriate.
💡 The best regimen is not necessarily the regimen with the most drugs; it is the one matched to the patient.
7. 🧑 Young-onset T2D deserves special cardiometabolic attention.
Compared with later-onset T2D, young-onset patients had persistently higher HbA1c and LDL-C and underwent HbA1c/LDL-C testing less frequently. The LDL-C disparity did not narrow with time.
💡 Don't treat young age as cardiovascular reassurance.
8. 📱 Adolescence → young adulthood is a vulnerable diabetes transition.
Among 1,631 people aged 11–22 years with T1D, only about 22% met both stated CGM targets, and target attainment declined with increasing age; hyperglycaemia was the major barrier.
💡 Technology needs to be accompanied by age-specific behavioural and healthcare support.
9. 🔥 Tirzepatide early in T2D: beyond HbA1c and kilograms.
At 104 weeks in SURPASS-EARLY, HbA1c fell to 5.56% vs 6.35% with intensified conventional care, while weight fell by about 15.8 vs 6.5 kg. OGTT-derived measures also indicated greater improvement in β-cell function and insulin sensitivity.
💡 This raises an important concept: early incretin-based treatment may modify multiple components of the metabolic phenotype—not simply glucose.
10. 💉 Before simply escalating basal insulin, reconsider the strategy.
In SUSTAIN OPTIMIZE, adding semaglutide 2.0 mg weekly while reducing basal insulin produced greater HbA1c reduction, 8-kg weight loss, lower insulin requirement and TIR 81.2% vs 64.3% with titrated glargine alone—roughly 4 extra hours/day in range, without increased TBR.
💡 Sometimes the better intensification is less insulin + an effective complementary therapy, rather than progressively more basal insulin.
11. 🎯 In DKD, look beyond BMI—visceral adiposity may matter.
In T2D with visceral obesity, >10% reduction in visceral fat area was associated with more albuminuria improvement and slower eGFR decline; the VFA-reduction group had a 2.53-fold higher probability of albuminuria improvement.
💡 Where the fat is—and how it changes—may matter to the kidney. Importantly, this was an association from a prospective cohort, not proof of causality.
12. ⚡ Painful diabetic neuropathy may have a neuromodulation option in selected refractory patients.
With 10-kHz spinal cord stimulation, 93.1% of per-protocol participants achieved ≥50% pain reduction at 6 months versus 0% with conventional medical management; sensory improvement was also demonstrated and persisted through 12 months.
💡 Particularly interesting: the signal was not limited to analgesia—objective sensory-function improvement was also reported.
🔥 TAKE-HOME
Diabetes care in 2026 is moving from “lower the HbA1c” → to “identify the phenotype, protect the organs, preserve function and individualize early.”
The 5 shifts worth remembering:
eGFR → eGFR + UACR | Glucose → Glucose + Ketones | BMI → Adiposity phenotype | Stepwise failure → Timely combination | HbA1c → CGM + organ outcomes + quality of life
Source: Essence of EASD 2026, Milan, Day 2. These are conference-study findings as presented in the uploaded document; several should be viewed as emerging evidence rather than automatic changes to clinical guidelines.